Published in Vnitr Lek on December 01, 1986
Field mapping without reference scan using asymmetric echo-planar techniques. Magn Reson Med (2000) 3.13
Toward an in vivo neurochemical profile: quantification of 18 metabolites in short-echo-time (1)H NMR spectra of the rat brain. J Magn Reson (1999) 2.42
Assessment of adrenoleukodystrophy lesions by high field MRS in non-sedated pediatric patients. Neurology (2005) 1.73
[Relationship of the CDKAL1 and KCNQ1 gene polymorphisms to the age at diagnosis of type 2 diabetes in the Slovakian population]. Vnitr Lek (2011) 1.39
Extracellular-intracellular distribution of glucose and lactate in the rat brain assessed noninvasively by diffusion-weighted 1H nuclear magnetic resonance spectroscopy in vivo. J Cereb Blood Flow Metab (2000) 1.18
Absolute metabolite quantification by in vivo NMR spectroscopy: II. A multicentre trial of protocols for in vivo localised proton studies of human brain. Magn Reson Imaging (1998) 1.18
Noninvasive measurements of [1-(13)C]glycogen concentrations and metabolism in rat brain in vivo. J Neurochem (1999) 1.14
Single-shot, three-dimensional "non-echo" localization method for in vivo NMR spectroscopy. Magn Reson Med (2000) 1.08
Localized in vivo 1H NMR detection of neurotransmitter labeling in rat brain during infusion of [1-13C] D-glucose. Magn Reson Med (1999) 1.02
Effect of gene polymorphisms on lipoprotein levels in patients with dyslipidemia of metabolic syndrome. Physiol Res (2005) 0.83
Metabolic changes in rat brain after prolonged ethanol consumption measured by 1H and 31P MRS experiments. Cell Mol Neurobiol (2000) 0.81
Carotid intima-media thickness in relation to macrovascular disease in patients with type 2 diabetes mellitus. Wien Klin Wochenschr (2000) 0.80
Motion artifacts reduction in DWI using navigator echoes: a robust and simple correction scheme. MAGMA (1998) 0.78
Relationship among urinary albumin excretion rate, lipoprotein lipase PvuII polymorphism and plasma fibrinogen in type 2 diabetic patients. Physiol Res (2005) 0.78
Important contribution of lipoprotein particle number to plasma triglyceride concentration in type 2 diabetes. Atherosclerosis (1998) 0.77
Absolute metabolite quantification by in vivo NMR spectroscopy: III. Multicentre 1H MRS of the human brain addressed by one and the same data-analysis protocol. Magn Reson Imaging (1998) 0.77
[Hypercoagulation states]. Vnitr Lek (1993) 0.76
Type IV renal tubular acidosis associated with Alport's syndrome. Postgrad Med J (1993) 0.75
Application of NMR spectroscopy in biochemical studies of tumor cells sensitive and resistant to anticancer drugs. Neoplasma (1998) 0.75
New approach for quantitation of short echo time in vivo 1H MR spectra of brain using AMARES. NMR Biomed (1998) 0.75
[The effect of furosemide on vitamin C excretion in urine in chronic kidney failure]. Cas Lek Cesk (1986) 0.75
[Relation of polymorphism of genes controlling endothelial function and blood pressure and the occurrence of vascular complications in type 2 diabetes]. Vnitr Lek (2002) 0.75
[Infections of the diabetic foot--etiopathogenesis and possible preventive strategies]. Vnitr Lek (1998) 0.75
[Use of a computer for obtaining optimal serum sodium values at the end of hemodialysis]. Vnitr Lek (1990) 0.75
[Neurohumoral activity in liver cirrhosis]. Vnitr Lek (1995) 0.75
[Malignant ventricular arrhythmia in a heart transplant patient]. Bratisl Lek Listy (1998) 0.75
[Noninvasive electrocardiographic monitoring and ventricular arrhythmias in patients after myocardial infarct]. Bratisl Lek Listy (1996) 0.75
[Changes in lipoprotein metabolism in patients with diabetes mellitus and the effect on lipid profile in diabetics]. Vnitr Lek (1994) 0.75
Spirometric alterations in patients with reduced renal function. Wien Klin Wochenschr (1993) 0.75
[Diagnosis of chronic massive pulmonary thromboembolism in elderly patients]. Vnitr Lek (1996) 0.75
[Infection of the diabetic foot--appropriate antibiotics and therapeutic strategies]. Vnitr Lek (1998) 0.75
[Hereditary hemorrhagic telangiectasis and the development of an arteriovenous fistula after 24 years]. Vnitr Lek (1997) 0.75
[Cardiologic management in patients on a long-term dialysis program]. Bratisl Lek Listy (1995) 0.75
[Neuroendocrine changes in chronic heart failure]. Vnitr Lek (1993) 0.75
[Evans' syndrome]. Vnitr Lek (1988) 0.75
[Pulmonary embolism as a rare complication of a contusion in the inguinal region]. Vnitr Lek (1992) 0.75
[Effect of bisoprolol on heart rate variability in patients with hyperthyroidism]. Vnitr Lek (2000) 0.75
[The present status of treatment of unstable angina pectoris]. Vnitr Lek (1994) 0.75
[Pharmacotherapy of silent myocardial ischemia in patients on hemodialysis]. Vnitr Lek (1996) 0.75
[Calcium ions in the plasma during acetate and bicarbonate hemodialysis]. Cas Lek Cesk (1987) 0.75
Cardiovascular risk factors as predictors of mortality in type II diabetic patients. Wien Klin Wochenschr (1999) 0.75
[Echocardiographic findings in patients on a long-term dialysis regimen]. Vnitr Lek (1988) 0.75
[Treatment of autonomous thyroid gland nodules using percutaneous injections of ethanol under ultrasonography control--initial experience]. Vnitr Lek (1996) 0.75
[10 years' experience with hemoperfusion in the treatment of acute poisoning--clinical analysis of 122 patients]. Vnitr Lek (1987) 0.75
[ECG Holter monitoring in patients with chronic renal failure in a long-term dialysis program]. Vnitr Lek (1992) 0.75
[Use of hemoperfusion and cholinesterase in acute poisoning with organophosphate cholinesterase inhibitors--clinical analysis of 50 patients]. Vnitr Lek (1992) 0.75